Rebecca Gardner

3.5k total citations · 2 hit papers
23 papers, 2.1k citations indexed

About

Rebecca Gardner is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Rebecca Gardner has authored 23 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Immunology and 5 papers in Genetics. Recurrent topics in Rebecca Gardner's work include CAR-T cell therapy research (17 papers), Virus-based gene therapy research (4 papers) and Immune Cell Function and Interaction (4 papers). Rebecca Gardner is often cited by papers focused on CAR-T cell therapy research (17 papers), Virus-based gene therapy research (4 papers) and Immune Cell Function and Interaction (4 papers). Rebecca Gardner collaborates with scholars based in United States, Australia and Germany. Rebecca Gardner's co-authors include Michael C. Jensen, Stanley R. Riddell, Olivia Finney, Cameron J. Turtle, Corinne Summers, Colleen Annesley, Hannah Smithers, Marie Bleakley, David G. Maloney and Kasey J. Leger and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Rebecca Gardner

21 papers receiving 2.0k citations

Hit Papers

Intent-to-treat leukemia remission by CD19 CAR T cells of... 2016 2026 2019 2022 2017 2016 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
    2017 787 citations Rebecca Gardner, Olivia Finney et al. Blood profile →
  2. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
    2016 544 citations Rebecca Gardner, Olivia Finney et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rebecca Gardner United States 13 1.8k 592 514 504 446 23 2.1k
Nicholas Tschernia United States 7 2.1k 1.1× 656 1.1× 590 1.1× 558 1.1× 614 1.4× 20 2.3k
D. Stroncek United States 5 2.1k 1.2× 652 1.1× 580 1.1× 556 1.1× 665 1.5× 12 2.3k
Colleen Annesley United States 19 1.5k 0.8× 450 0.8× 445 0.9× 392 0.8× 305 0.7× 52 1.8k
Elad Jacoby Israel 22 1.5k 0.8× 505 0.9× 818 1.6× 335 0.7× 528 1.2× 76 2.2k
Cindy Delbrook United States 16 2.9k 1.6× 880 1.5× 760 1.5× 715 1.4× 792 1.8× 27 3.3k
Corinne Summers United States 15 1.3k 0.7× 411 0.7× 319 0.6× 343 0.7× 253 0.6× 42 1.5k
Maksim Mamonkin United States 19 1.8k 1.0× 691 1.2× 738 1.4× 377 0.7× 746 1.7× 59 2.1k
Catherine Lindgren United States 19 2.5k 1.4× 801 1.4× 691 1.3× 643 1.3× 1.1k 2.4× 40 2.9k
Antonio Di Stasi United States 16 2.2k 1.2× 916 1.5× 887 1.7× 648 1.3× 954 2.1× 42 2.8k

Countries citing papers authored by Rebecca Gardner

Since Specialization
Citations

This map shows the geographic impact of Rebecca Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Gardner more than expected).

Fields of papers citing papers by Rebecca Gardner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Gardner. The network helps show where Rebecca Gardner may publish in the future.

Co-authorship network of co-authors of Rebecca Gardner

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Gardner. A scholar is included among the top collaborators of Rebecca Gardner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Gardner. Rebecca Gardner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Krantz, Elizabeth M., Julián B. Muñoz, Andrew J. Cowan, et al.. (2025). Distinct Patterns of Pathogen-Specific and Non-Specific Immune Reconstitution after CD19/20- Versus BCMA-Targeted CAR-T Cell Therapy. Transplantation and Cellular Therapy. 31(2). S71–S71.
2.
Mackall, Crystal L., Catherine M. Bollard, Rebecca Gardner, et al.. (2024). Enhancing pediatric access to cell and gene therapies. Nature Medicine. 30(7). 1836–1846. 13 indexed citations
3.
Hill, Joshua A., Jim Boonyaratanakornkit, Rebecca Gardner, et al.. (2023). Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy. American Journal of Transplantation. 23(3). 416–422. 10 indexed citations
4.
Walti, Carla S., Andrea N. Loes, Kiel Shuey, et al.. (2021). Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study. Journal for ImmunoTherapy of Cancer. 9(10). e003428–e003428. 32 indexed citations
5.
Walti, Carla S., Elizabeth M. Krantz, Joyce Maalouf, et al.. (2021). Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. JCI Insight. 6(11). 37 indexed citations
6.
Jensen, Michael C., Seth L. Masters, James E. Vince, et al.. (2021). Poor Clinical Outcome in Pediatric Immunotherapy Is Mediated By a Pre-Existing Overactive IL-18-IFNy Immune Phenotype. Blood. 138(Supplement 1). 168–168. 1 indexed citations
7.
Gardner, Rebecca, Olivia Finney, Hannah Brakke, et al.. (2018). Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy. Blood. 132(Supplement 1). 4022–4022. 11 indexed citations
8.
Summers, Corinne, Colleen Annesley, Marie Bleakley, et al.. (2018). Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission. Blood. 132(Supplement 1). 967–967. 33 indexed citations
9.
Ranger, Ann, Soma Ray, Suzanne Szak, et al.. (2017). Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies. Neurology Neuroimmunology & Neuroinflammation. 5(1). e417–e417. 25 indexed citations
10.
Tsuchiya, Karen D., et al.. (2017). Is intrachromosomal amplification of chromosome 21 (iAMP21) always intrachromosomal?. Cancer Genetics. 218-219. 10–14. 9 indexed citations
11.
12.
Gardner, Rebecca, Kasey J. Leger, Colleen Annesley, et al.. (2016). Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management. Blood. 128(22). 586–586. 50 indexed citations
13.
Jacoby, Elad, Sang M. Nguyen, Thomas J. Fountaine, et al.. (2016). CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nature Communications. 7(1). 12320–12320. 293 indexed citations
14.
Gardner, Rebecca, Olivia Finney, Hannah Smithers, et al.. (2016). Prolonged functional persistence of CD19CAR t cell products of defined CD4:CD8 composition and transgene expression determines durability of MRD-negative ALL remission.. Journal of Clinical Oncology. 34(15_suppl). 3048–3048. 13 indexed citations
15.
16.
Whitlock, James A., Luciano Dalla Pozza, John M. Goldberg, et al.. (2014). Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL). Blood. 124(21). 795–795. 13 indexed citations
17.
Terakura, Seitaro, Tori N. Yamamoto, Rebecca Gardner, et al.. (2011). Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood. 119(1). 72–82. 158 indexed citations
18.
19.
Löndt, Brandon Z., Jill Banks, Rebecca Gardner, W. J. Cox, & Ian H. Brown. (2007). Induced Increase in Virulence of Low Pathogenic Avian Influenza by Serial Intracerebral Passage in Chickens. Avian Diseases. 51(s1). 396–400. 8 indexed citations
20.
Eastwood, D. W., et al.. (1964). EFFECT OF NITROUS OXIDE ON THE WHITE-CELL COUNT IN LEUKEMIA. Survey of Anesthesiology. 8(3). 219???220–219???220. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicholas Tschernia Breakdown of academic impact, for papers by D. Stroncek Breakdown of academic impact, for papers by Colleen Annesley Breakdown of academic impact, for papers by Elad Jacoby Breakdown of academic impact, for papers by Cindy Delbrook Breakdown of academic impact, for papers by Corinne Summers Breakdown of academic impact, for papers by Maksim Mamonkin Breakdown of academic impact, for papers by Catherine Lindgren Breakdown of academic impact, for papers by Antonio Di Stasi
Rankless by CCL
2026